Parallax Volatility Advisers
NVLN

Parallax Volatility Advisers’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Parallax Volatility Advisers’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,400
Closed -$79K – 5049
2016
Q4 		$79K Buy
+9,400
New +$83.3K ﹤0.01% 2301

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Parallax Volatility Advisers's NVLN Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2018, closing a stake of 2,310 shares — an estimated $7K sold.

Parallax Volatility Advisers first reported a position in NVLN in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 68 funds tracked by Wall St. Rank hold NVLN as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,310 Novelion Therapeutics Inc. Common Shares shares in Q1 2018, an estimated $7K.
  • Parallax Volatility Advisers first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Novelion Therapeutics Inc. Common Shares position peaked at $7K in Q4 2017.
  • 68 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.